

University of Maryland  
Department of Radiation Oncology

Schedule of  
Presentations and Activities



**2023 Annual Meeting**  
**San Diego, California**  
**October 1-4**

## Sunday, October 1 Presentations

### 4:45 PM

Clinical efficacy and safety of once-weekly fractionation in stereotactic body radiotherapy for pulmonary oligometastatic lesions

**Allen A**, Labella D, Harris E, Kowalchuk RO, Waters MR, Richardson KM

Poster 2002

Session PQA 01, Hall B2

### 4:45 PM

The Society for Women in Radiation Oncology: Where are we five years later?

**Krc R**, Lichter K, Jatar S, Seldon Taswell C, Beltran Ponce S, MacDuffie E, LeCompte M, Chen J, Wang K, LoTempio A, Saripalli A, Kaya E, Barry P, Henson Masters A, Jagsi R, Kahn J

Poster 2068

Session PQA 01, Hall B2

### 4:45 PM

Identifying and addressing nutritional inequities and psychosocial needs of cancer patients residing in zip-code designated food priority areas (FPAs)

LePore LE, Kronfli D, **Baker K**, **Eggleston C**, **Bentzen S**, Mohindra P, **Vyfhuis M**

Poster 2074

Session PQA 01, Hall B2

### 4:45 PM

Cardiopulmonary toxicity from intensity modulated proton therapy for thymic malignancies

Rao M, **Rana Z**, **Redell D**, **Alicia D**, Glass E, Burrows W, Friedberg J, Scilla K, Mehra R, Rolfo C, Simone CB, Mohindra P

Poster 2108

Session PQA 01, Hall B2

### 4:55 PM

A precision medicine navigator can mitigate inequities associated with utilization of genomic tests in black men with prostate cancer

**Allen A**, **Savla B**, **Datnow-Martinez C**, **Mendes W**, Kamran S, Ambs S, **Eggleston C**, **Baker K**, **Molitoris JK**, **Ferris MJ**, **Patel A**, **Rana Z**, **Kunaprayoon D**, **Hong J**, Davicioni E, **Bentzen S**, **Mishra MV**, **Regine W**, **Kwok Y**, **Vyfhuis M**

Oral, abstract 122

Session SS 05 DEIH 1, Rm 4

## University of Maryland and Department of Radiation Oncology Welcome Dinner Reception

Sunday, October 1

6:30–9:30 PM

San Diego Wine & Culinary Center

200 Harbor Drive, Suite 120

San Diego, CA

## Monday, October 2 Presentations

**8:30 AM**

Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation

Deek M, **Shetty A**, Song Y, Efstathiou J, Feng F, Shipley W, Simko J, Mouw K, Miyamoto D, Pollack A, Michaelson MD, Zietman A, Coen J, Dahl D, Jani A, Souhami L, Chang BK, Lee RJ, Thanh Pham H, Rodgers J, **Tran P**

Oral

Session SS 07 Bio 2, Rm 4

**10:45 AM**

Conditional survival estimates for malignant glioma patients by RPA class: Secondary analysis of RTOG 9006

**Brown M, Cherg HR, Assif J, Sun K, Mishra M**

Poster 2200

Session PQA 02, Hall B2

**10:45 AM**

Estimation of conditional neurocognitive function failure (NCFF) incidence in patients receiving whole brain radiation therapy (WBRT) for brain metastases (BM): Secondary analysis of NRG CC001

**Cherg HR, Sun K, Bentzen S, Mishra M**

Poster 2208

Session PQA 02, Hall B2

**11:32 AM**

Transitions in the early career: Community practice to academics

**McAvoy S**

Oral

Session EDU 09, Room 31

**2:40 PM**

Randomized controlled trial of hypofractionated vs. normo-fractionated accelerated radiation therapy with or without cisplatin for locally advanced head and neck squamous cell carcinoma (HYPNO)

**Bentzen S**, Rosenblatt E, Gupta T, Agarwal JP, Laskar SG, Bhasker S, Jacinto AA, De Marchi P, Nagarajan M, Jabeen K, Binia S, Chansilpa Y, Napoles M, Aguiar S, Goloubeva O, Zubizarreta E, Hopkins K, Abdel-Wahab M

Oral, plenary

Session PL 01 Plenary, Ballroom 20

**3:00 PM**

Decreasing skin toxicity in whole breast irradiation with helical tomotherapy IMRT

Alphonse A, Richter S, Whalen S, **Benda R**

Poster 2350

Session PQA 03, Hall B2

## Department Members Highlighted in ASTRO News Briefing

Monday, October 2

11:00 AM–12:00 PM PT (2:00–3:00 PM ET)

Room 26 | [Register to attend the Zoom webcast](#)

**Søren Bentzen, PhD, DMSc, FASTRO**—Randomized controlled trial of hypofractionated vs. normo-fractionated accelerated radiation therapy with or without cisplatin for locally advanced head and neck squamous cell carcinoma (HYPNO)

**Alexander Allen, MD**—A precision medicine navigator can mitigate inequities associated with utilization of genomic tests in black men with prostate cancer

## Monday, October 2 Presentations (cont.)

### 3:10 PM

Validation of a genomic classifier in the NRG Oncology/RTOG 0521 randomized phase III trial of docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer

Phillips R, Proudfoot J, Davicioni E, Spratt D, Feng F, Simko J, Den RB, Pollack A, Rosenthal S, Sartor AO, Sweeney C, Attard G, Patel S, Hall W, Efstathiou J, Shah A, Hoffman K, Pugh S, Sandler H, **Tran P**

Oral

Session SS 11 GU3, Room 6 D/E

### 3:14 PM

Oligometastatic prostate cancer: Case discussion

**Tran PT**

Oral, panel presentation

Session SS, Rm 6 C/F

### 3:40 PM

PSMA-positive extracellular vesicles predict disease recurrence in oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy: Analysis of the ORIOLE trial

Horjeti E, Kim Y, Arafa A, Sutera P, Phillips R, Song D, Kiess A, **Tran P**, Park S, Lucien F

Oral

Session SS 11 GU3, Room 6 D/E

### 5:00 PM

Pancreatic cancer derived 3D organoids as clinical tool to predict response to radiation and chemo-radiation therapy

Roy S, **Dukic T**, **Bhandary B**, Keepers Z, **Lamicchane N**, Ko YH, **Molitoris J**, **Carrier F**, **Regine WF**, **Shukla HD**

Poster 2561

PQA 04, Hall B2

### 5:00 PM

Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Sutera P, **Shetty A**, Hakansson A, Van der Eecken K, Song Y, Liu YS, Fonteyne V, Verbeke S, Song D, Ross A, Feng F, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, **Tran P**, Deek M, Ost P

Poster 2567

PQA 04, Hall B2

## Tuesday, October 3 Presentations

### 8:00 AM

Phys 5: Motion and imaging. Hybrid-supervised deep learning for proton-acoustic reconstruction for 3D in vivo proton dose verification

**Lang Y**, Jiang Z, Sun L, Xiang L, **Ren L**

Moderator

QP 08, Rm 8

## Congratulations to Department Award Winners

Tuesday, October 3

10:15–11:00 AM Ballroom 20

**Phuoc Tran, MD, PhD**—2023 Mentorship Award

**Alexander Allen, MD**—2023 Resident Clinical/Basic Science Research Award

**Hua-Ren Cherng, MD**—2023 Resident Recognition Award/Poster Viewing

### Tuesday, October 3 Presentations (cont.)

**2:30 PM**

Conditional prostate cancer-specific survival probabilities in recurrent prostate cancer patients receiving radiation  $\pm$  antiandrogen therapy: Secondary analysis of a randomized clinical trial

**Assif JW, Alexander GS, Krc R, Sun K, Molitoris JK, Tran PT, Bentzen SM, Rana Z, Mishra M**

Poster 2799

PQA 06, Hall B2

**2:30 PM**

Prospective characterization of circulating tumor cells in hormone sensitive oligometastatic prostate cancer patients on a metastasis-directed therapy trial

**Bazyar S, Sutera P, Phillips R, Deek MP, Radwan N, Marshall CH, Mishra MV, Rana ZH, Molitoris JK, Kwok Y, Gupta S, Wenstrup R, DeWeese TL, Song D, Feng FY, Pienta K, Antonarakis ES, Kiess AP, Tran PT**

Poster 2804

PQA 06, Hall B2

**2:30 PM**

Patterns of adaptive replanning in proton therapy for thoracic malignancies

**Hamza M, Biswal C, Assif JW, Yi BY, Zhang B, Alicia D, Redell D, Eggleston C, Van Eck R, Ferris MH, Mohindra P, Rana Z**

Poster 2851

PQA 06, Hall B2

**2:30 PM**

Concurrent radiation and deep hyperthermia therapy for the treatment of recurrent prostate cancer

**Hamza M, Cohen JD, Chen L, Rodrigues D, Mossahebi S, Biswal NC, Zakhary M, Kunaprayoon D, Rana Z, Molitoris JK**

Poster 2852

PQA 06, Hall B2

**2:30 PM**

The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer

**Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, Shetty A, Chowdhury D, Chan A, Carrieri F, Song D, DeWeese T, Lafargue A, Van der Eecken K, Bunz F, Ost P, Tran P, Deek M**

Poster 2966

PQA 06, Hall B2

## Tuesday, October 3, Presentations (cont.)

### 2:30 PM

Identification of a predictive genomic biomarker for prostate directed therapy in synchronous low-volume metastatic castration sensitive prostate cancer

Sutera P, **Shetty A**, Song Y, Hodges T, Hoang T, **Rana Z**, Pienta K, Feng F, Song D, DeWeese T, Gillessen S, James N, Attard G, Deek M, **Tran P**

Poster 2964

PQA 06, Hall B2

### 2:30 PM

Multi-institutional analysis of metastasis directed therapy with or without androgen deprivation therapy in oligometastatic castration sensitive prostate cancer

Sutera P, Deek M, Jing Y, Pryor D, Huynh MA, Koontz B, Mercier C, Ost P, Kiess A, Conde-Moreno A, Stish B, Bosetti DG, Siva S, Berlin A, Kroeze S, Corcoran N, Trock B, Gillessen S, **Tran P**, Sweeney C

Poster 2965

PQA 06, Hall B2

### 2:30 PM

Evolving roles of medical physicists in clinical trials

**Ren L**

Moderator

Session EDU 24, Rm 29

### 2:56 PM

Emerging role of medical physicists in virtual clinical trials

**Ren L**

Oral

Session EDU 24, Rm 29

### 3:20 PM

The role of clinicians in support of implementing physicist-directed emerging technologies through clinical trials

**Molitoris J**

Oral

Session EDU 24, Rm 29

### 5:15 PM

Impact of testosterone recovery on clinical outcomes of patients treated with salvage radiotherapy and androgen suppression: a secondary analysis of the NRG/RTOG 0534 SPPORT phase 3 trial

Dal Pra A, Lyness J, Pollock A, **Tran P**, Koontz B, Abramowitz M, Mahal B, Martin A-G, Michalski J, Balogh A, Lukka H, Faria S, Rodrigues G, Beauchemin M-C, Lee RJ, Seaward S, Coen S, **Allen A**, Pugh S, Feng F

Oral

Session SS 28 GU4, Rm 6B

### 5:20 PM

Automatic prediction of metastasis-free survival (MFS) using prostate-specific membrane antigen (PSMA) PET for oligometastatic castration-sensitive prostate cancer (omCSPC)

**Cao Y**, Sutera P, Mendes WS, Yousefi B, Hrinivich T, Deek M, Phillips R, Song D, Kiess A, Guler OC, Torun N, Reyhan M, **Tran P**, Onal C, **Ren L**

Oral quick pitch, 1182

Session QP 17, Rm 7

## Wednesday, October 4, Presentations

### 10:30 AM

Outcomes of patients treated with re-irradiation for recurrent head and neck cancer using pencil beam scanning proton therapy

**Krc R, Mendes W, Molitoris J, Ferris M, Yang S, Shetty A, Mehra R, Papadimitriou J, Hatten K, Taylor R, Wolf J, Sun K, Bentzen S, Regine W, Tran P, Witek M**

Poster 3300

Session PQA 09, Hall B2

### 10:50 AM

Conditional risk and predictive factors associated with late toxicity for prostate cancer patients treated with external beam radiotherapy alone on randomized trial RTOG 0126

**Alexander GS, Krc R, Assif J, Sun K, Molitoris JK, Tran P, Bentzen SM, Rana Z, Mishra M**

Oral

SS 32 G5, Rm 1

### 12:30 PM

Relationship between spatial distribution tumor location and dosimetric outcomes in patients receiving definitive proton therapy for locally advanced lung cancer

**Cherng HR, Alexander GS, Mohindra P, Alicia D, Redell D, Eggleston C, Van Eck R, Kunaprayoon D, Vyfhuis MAL, Patel AN, Molitoris JK, Ferris MJ, Rana Z**

Poster 3433

Session PQA 10, Hall B2

### 12:30 PM

Pelvis treatment plan dose comparison for proton therapy using single energy and dual energy computed tomography simulation methods

**Sabouri P, Koroulakis A, Cusatis D, Lehman, K, Wohlfahrt, Shah J, Molitoris JK, Mossahebi S**

Poster 3531

Session PQA 10, Hall B2